Cons: lower per-capsule dose (175 mg) means you need 2-4 capsules daily, higher cost per effective dose than standard capsules, no Setria certification, sustained-release clinical data is less robust than liposomal data
Why it was included in the FDA ban The FDA cites risk for immunogenicity, peptide-related impurities, and limited safety-related information as reasons for the BPC-157 ban
How Soon Will You See Results From Lipo Shots
It is not approved for human or veterinary use, clinical administration, therapeutic applications, or diagnostic procedures of any kind
These diabetes-specific results mirror the pattern seen with CagriSema in REDEFINE 2, though direct comparison requires caution because the trial populations and designs differed
There are other arguments I can make